Cost Effectiveness of Insulin Glargine plus Oral Antidiabetes Drugs Compared with Premixed Insulin Alone in Patients with Type 2 Diabetes Mellitus in Canada
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Background Several treatment options are available for patients with type 2 diabetes mellitus who are making the transition from oral antidiabetes drugs (OADs) to insulin. Two options currently recommended by the Canadian Diabetes Association for initiating insulin therapy in patients with type 2 diabetes who are no longer responsive to OADs alone are insulin glargine plus OADs, and premixed insulin therapy only. Because of differences in efficacy, adverse events (such as hypoglycaemia) and acquisition costs, these two treatment options may lead to different long-term clinical and economic outcomes. Objective To determine the cost effectiveness of insulin glargine plus OADs compared with premixed insulin without OADs in insulin-naive patients with type 2 diabetes in Canada. Methods Using treatment effects taken from a published clinical trial, the validated IMS-CORE Diabetes Model was used to simulate the long-term cost effectiveness of insulin glargine with OADs, versus premixed insulin. Input treatment effects for the two therapeutic approaches were based on changes in glycosylated haemoglobin A(1c) (HbA(1c)) at clinical trial endpoint, and hypoglycaemia rates. The analysis was conducted from the perspective of the Canadian Provincial payer. Direct treatment and complication costs were obtained from published sources (primarily from Ontario) and reported in $Can, year 2008 values. All base-case costs and outcomes were discounted at 5% per year. Sensitivity analyses were con…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Basal insulin analogs are preferred over NPH insulin because of a reduced risk of hypoglycemia.1066–1071”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1071]
Citations
Cites
Preference-Based EQ-5D Index Scores for Chronic Conditions in the United States
Sullivan, P. W., & Ghushchyan, V. (2006) · Medical Decision Making · doi:10.1177/0272989x06290495 · Cited by 705
Primary and subsequent coronary risk appraisal: New results from the Framingham study
D'Agostino, R. B., Russell, M. W., Huse, D. M., Ellison, R. C., Silbershatz, H., Wilson, P. W. F., & Hartz, S. C. (2000) · American Heart Journal · doi:10.1016/s0002-8703(00)90236-9 · Cited by 589
Palmer, A. J., Roze, S., Valentine, W. J., Minshall, M. E., Foos, V., Lurati, F. M., Lammert, M., & Spinas, G. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x1980 · Cited by 526
Self-citationEstimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)
Clarke, P., Gray, A., & Holman, R. (2002) · Medical Decision Making · doi:10.1177/027298902400448902 · Cited by 515
Janka, H. U., Plewe, G., Riddle, M. C., Kliebe-Frisch, C., Schweitzer, M. A., & Yki-Järvinen, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.254 · Cited by 414
The Prevalence and Incidence of Lower Extremity Amputation in a Diabetic Population
Moss, S. E. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.152.3.610 · Cited by 325
Health care and health status and outcomes for patients with type 2 diabetes.
Harris, M. I. (2000) · Diabetes Care · doi:10.2337/diacare.23.6.754 · Cited by 306
Hypoglycaemia in insulin‐treated Type 2 diabetes: frequency, symptoms and impaired awareness
Henderson, J. N., Allen, K. V., Deary, I. J., & Frier, B. M. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01072.x · Cited by 287
Research works printed but not linked: 3
- 2008, Can J Diabetes, 32, 1
- Moss, 1992, Arch Inter Med, 152, 610, 10.1001/archinte.1992.00400150120022 · doi:10.1001/archinte.1992.00400150120022 · Paper page
- Currie, 2005, Diabetologia, 48, A292
Cited by
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Metadata
- Authors
- Tunis, S. L., Sauriol, L., & Minshall, M. E.
- Affiliations
- IQVIA (United States) (US)
- Sanofi (Canada) (CA)
- Corresponding author
- Sauriol, Luc
- Venue
- Applied Health Economics and Health Policy
- Published
- 2010-07
- Volume
- 8
- Issue
- 4
- Pages
- 267-280
- ISSN
- 1175-5652 (ISSN-L)
- OpenAlex
- W1994423404
- Cited by
- 21
- References
- 26
- Citations by year
- 2022: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 3 · 2015: 5 · 2014: 2 · 2013: 2 · 2012: 2
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Applied Health Economics and Health Policy (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Sanofi
- Public Health Agency of Canada
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- insulin glargine, oral antidiabetic drugs, premixed insulin, type 2 diabetes, cost-effectiveness, insulin initiation, hypoglycemia, glycemic control, diabetes complications, quality-adjusted life years, incremental cost-effectiveness ratio, Ontario, willingness to pay
- MeSH terms
- Insulin Glargine, Canada, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Sulfonylurea Compounds, Quality-Adjusted Life Years, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost Effectiveness of Insulin Glargine plus Oral Antidiabetes Drugs Compared with Premixed Insulin Alone in Patients with Type 2 Diabetes Mellitus in Canada. https://app.cochat.ai/papers/10.2165/11535380-000000000-00000
- The paper
- Tunis, S. L., Sauriol, L., & Minshall, M. E. (2010). Cost Effectiveness of Insulin Glargine plus Oral Antidiabetes Drugs Compared with Premixed Insulin Alone in Patients with Type 2 Diabetes Mellitus in Canada. Applied Health Economics and Health Policy. https://doi.org/10.2165/11535380-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.